Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes. 

The new guidance, published in the Journal of the American College of Cardiology, covers a variety of topics, including thoracic aortic disease, peripheral artery disease, shared decision-making and cardiac imaging.

Atrial fibrillation and peripheral artery disease, for example, are both predictors of mortality among women, but not men. 

New research out of Mayo Clinic found that clinicians who listened to AI-based treatment recommendations were more successful at identifying patients with low ejection fraction. 

Deepak Bhatt, MD, MPH, details long-term outcomes from the SYMPLICITY HTN-3 trial, which show a lasting impact on patients with uncontrolled hypertension. 

The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 

The American College of Cardiology and Heart Rhythm Society issued a joint statement soon after CMS published its final rule for the 2023 Medicare Physician Fee Schedule. The groups warned that the final rule could threaten patient access to high-quality care. 

“This was a true milestone for research on xenotransplantation," one specialist said. The full analysis is scheduled to be presented at the American Heart Association's Scientific Sessions 2022 in Chicago.